4^th World Congress On Protein and Bio-Medical Engineering

Biography

After completion of his postdoctoral training at University of Texas MD Anderson Cancer Center, Dr. Gautam Sethi joined Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore in 2008 as an Assistant Professor and was promoted to Associate Professor in 2015. The focus of his research over the past few years has been to elucidate the mechanism (s) of activation of oncogenic transcription factors such as NF-kB/STAT3 by carcinogens and inflammatory agents and the identification of novel inhibitors of these proteins for prevention of and therapy for cancer. The findings of his research work have so far resulted in more than two hundred scientific publications in high impact factor peer reviewed journals (with h index = 70) and several international awards. He currently serves as an Academic Editor for PLOS, editorial board member of Scientific Reports, Pharmacological Research, BMC Cancer, Frontiers in Pharmacology, Frontiers in Oncology, Journal of Natural Products in Cancer Prevention and Therapy, and ad-hoc reviewer for several other prestigious international journals.

Research Interest

he focus of his research over the past few years has been to elucidate the mechanism (s) of activation of transcription factors NF-κB and STAT3 by carcinogens and inflammatory agents and the identification of novel inhibitors of NF-κB and STAT3 for prevention of and therapy for cancer. From natural sources, his group has identified numerous small molecules that can suppress NF-κB and STAT3 activation and inhibit TNF/IL-6 signaling. Thus, these agents have potential treatment properties for numerous inflammatory diseases, including cancer and are not toxic. Moreover, the results his research work have so far resulted in more than hundred scientific publications in high impact factor peer reviewed journals and several international research awards.